Palisade Bio Provides Corporate Update and Reiterates Guidance
February 13, 2024 08:35 ET
|
Palisade Bio, Inc.
– Company announces strategic streamlining of Board to align with the current state of clinical development and corporate vision – Advancement of PALI-2108 for the treatment of moderate-to-severe...
Correction Notice of Palisade Bio’s Press Release Announcing the Appointment of Clinical Advisory Board Members
February 08, 2024 14:40 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for...
Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders
February 08, 2024 08:05 ET
|
Palisade Bio, Inc.
Bruce Sands, MD, MS., Dr. Burrill B. Crohn Professor of Medicine, Icahn School of Medicine at Mount Sinai and System Chief, Division of Gastroenterology, Mount Sinai Health SystemFlorian Rieder, MD,...
QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals
February 07, 2024 16:00 ET
|
QSAM Biosciences Inc.
Austin, TX, Feb. 07, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM) (“QSAM or the “Company”) has signed a definitive Agreement and Plan of Merger (the “Agreement”) providing for the...
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split
February 01, 2024 11:00 ET
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), a clinical stage immuno-oncology company focused on developing innovative therapeutics...
Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million
January 30, 2024 09:25 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for...
Palisade Bio Selected for Poster Presentation at the 2024 Crohn’s & Colitis Congress
January 09, 2024 08:00 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious...
Hepion Pharmaceuticals to Present at NASH-TAG 2024
January 03, 2024 17:15 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Visiox Pharmaceuticals, Inc., a Commercial-Stage Biopharmaceutical Company to be Listed on Nasdaq Through a Business Combination with PowerUp Acquisition Corp.
December 27, 2023 08:01 ET
|
PowerUp Acquisition Corp.
Tarrytown, NY and New York, NY, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Visiox Pharmaceuticals, Inc. (“Visiox” or the “Company”), a commercial-stage biopharmaceutical company, and PowerUp Acquisition...
Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024
December 15, 2023 16:15 ET
|
Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC QB: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective...